Creative Planning’s Thermo Fisher Scientific TMO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$63.6M Buy
129,348
+5,093
+4% +$2.76M 0.04% 182
2025
Q4
$72M Buy
124,255
+1,459
+1% +$825K 0.05% 156
2025
Q3
$59.6M Buy
122,796
+11,027
+10% +$5.13M 0.05% 160
2025
Q2
$45.3M Buy
111,769
+9,086
+9% +$3.8M 0.04% 189
2025
Q1
$51.1M Sell
102,683
-1,743
-2% -$944K 0.05% 154
2024
Q4
$54.3M Buy
104,426
+3,252
+3% +$1.79M 0.05% 136
2024
Q3
$62.6M Buy
101,174
+3,072
+3% +$1.82M 0.06% 120
2024
Q2
$54.3M Buy
98,102
+2,668
+3% +$1.53M 0.06% 126
2024
Q1
$55.5M Buy
95,434
+6,428
+7% +$3.61M 0.06% 122
2023
Q4
$47.2M Sell
89,006
-27,935
-24% -$13.5M 0.09% 126
2023
Q3
$59.2M Buy
116,941
+36,587
+46% +$19.5M 0.08% 111
2023
Q2
$41.9M Sell
80,354
-1,918
-2% -$1.04M 0.06% 130
2023
Q1
$47.4M Buy
82,272
+1,641
+2% +$925K 0.07% 119
2022
Q4
$44.4M Buy
80,631
+6,469
+9% +$3.43M 0.07% 122
2022
Q3
$37.6M Sell
74,162
-4,773
-6% -$2.67M 0.07% 119
2022
Q2
$42.9M Buy
78,935
+6,275
+9% +$3.45M 0.07% 116
2022
Q1
$42.9M Buy
72,660
+39,944
+122% +$22.9M 0.07% 121
2021
Q4
$21.8M Buy
32,716
+680
+2% +$425K 0.04% 175
2021
Q3
$18.3M Buy
32,036
+273
+0.9% +$150K 0.03% 184
2021
Q2
$16M Sell
31,763
-5,567
-15% -$2.63M 0.03% 198
2021
Q1
$17M Buy
37,330
+1,570
+4% +$749K 0.03% 193
2020
Q4
$16.7M Buy
35,760
+1,221
+4% +$572K 0.04% 183
2020
Q3
$15.3M Buy
34,539
+5,011
+17% +$2.07M 0.04% 168
2020
Q2
$10.7M Sell
29,528
-5
-0% -$1.68K 0.03% 183
2020
Q1
$8.38M Sell
29,533
-340
-1% -$107K 0.03% 183
2019
Q4
$9.71M Buy
29,873
+575
+2% +$174K 0.03% 193
2019
Q3
$8.53M Sell
29,298
-1,191
-4% -$341K 0.03% 204
2019
Q2
$8.95M Buy
30,489
+1,369
+5% +$377K 0.03% 196
2019
Q1
$7.97M Buy
29,120
+674
+2% +$168K 0.03% 201
2018
Q4
$6.37M Buy
28,446
+1,831
+7% +$430K 0.03% 206
2018
Q3
$6.5M Buy
26,615
+1,385
+5% +$319K 0.02% 229
2018
Q2
$5.23M Buy
25,230
+1,977
+9% +$420K 0.02% 247
2018
Q1
$4.8M Buy
23,253
+233
+1% +$48.9K 0.02% 254
2017
Q4
$4.37M Buy
23,020
+2,592
+13% +$497K 0.02% 267
2017
Q3
$3.87M Buy
20,428
+3,433
+20% +$622K 0.02% 288
2017
Q2
$2.96M Sell
16,995
-248
-1% -$41.7K 0.02% 329
2017
Q1
$2.65M Sell
17,243
-1,085
-6% -$166K 0.01% 346
2016
Q4
$2.59M Buy
18,328
+2,007
+12% +$296K 0.02% 329
2016
Q3
$2.6M Buy
16,321
+3,744
+30% +$577K 0.02% 325
2016
Q2
$1.86M Buy
12,577
+3,255
+35% +$480K 0.01% 349
2016
Q1
$1.32M Sell
9,322
-1,696
-15% -$227K 0.01% 420
2015
Q4
$1.56M Sell
11,018
-459
-4% -$61.2K 0.01% 371
2015
Q3
$1.4M Buy
11,477
+1,268
+12% +$165K 0.01% 381
2015
Q2
$1.32M Sell
10,209
-194
-2% -$25.3K 0.01% 391
2015
Q1
$1.4M Sell
10,403
-2,079
-17% -$268K 0.01% 360
2014
Q4
$1.56M Buy
12,482
+3,238
+35% +$394K 0.02% 329
2014
Q3
$1.13M Buy
9,244
+1,418
+18% +$172K 0.01% 362
2014
Q2
$923K Buy
7,826
+574
+8% +$67.6K 0.01% 411
2014
Q1
$872K Sell
7,252
-185
-2% -$22K 0.01% 418
2013
Q4
$828K Buy
7,437
+536
+8% +$53.3K 0.01% 361
2013
Q3
$636K Buy
6,901
+522
+8% +$47.2K 0.01% 376
2013
Q2
$540K Buy
+6,379
New +$531K 0.01% 386

Other funds holding TMO

Creative Planning's TMO Position: Q1 2026 in Review

Creative Planning increased its Thermo Fisher Scientific (TMO) stake by 4.1% in Q1 2026, buying an estimated $2.76M and bringing the position to 129,348 shares worth $63.6M. The position accounts for 0.04% of the portfolio, ranked #182.

Creative Planning first reported a position in TMO in Q2 2013 and has held it in 52 quarters since. The position peaked at $72M in Q4 2025. 2,587 funds tracked by Wall St. Rank hold TMO as of Q1 2026.

  • Creative Planning held 129,348 shares of Thermo Fisher Scientific worth $63.6M as of Q1 2026.
  • Creative Planning bought 5,093 Thermo Fisher Scientific shares in Q1 2026, an estimated $2.76M.
  • Thermo Fisher Scientific made up 0.04% of Creative Planning's portfolio in Q1 2026, its #182 holding.
  • Creative Planning first reported a position in Thermo Fisher Scientific in Q2 2013 and has held it in 52 quarters since.
  • Creative Planning's Thermo Fisher Scientific position peaked at $72M in Q4 2025.
  • 2,587 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.